Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RELB |
| Gene Name: | RELB |
| Protein Full Name: | Transcription factor RelB |
| Alias: | I-Rel; REL-B; V-rel reticuloendotheliosis viral oncogene B |
| Mass (Da): | 62134 |
| Number AA: | 579 |
| UniProt ID: | Q01201; D6R992 |
| Locus ID: | 5971 |
| COSMIC ID: | RELB |
| Gene location on chromosome: | 19q13.32 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20337 |
| Percent of cancer specimens with mutations: | 0.36 |
| Normal role description: | RELB is a transcription factor which functions to induce transcription of target genes upon activation. RELB can interact with membranes of the IkB family (NF-kB) and Rel family to cause dimerization, whereby only heterodimerization with NF-kB is activating. Dimerization will cause RELB-NF-kB dimers to be translocated to the nucleus where it will interact with target gene sequences to cause transactivation. Mutations of RELB have been detected in ovarian cancer but their functional effects are not well characterized. |